[go: up one dir, main page]

CL2010001577A1 - Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. - Google Patents

Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.

Info

Publication number
CL2010001577A1
CL2010001577A1 CL2010001577A CL2010001577A CL2010001577A1 CL 2010001577 A1 CL2010001577 A1 CL 2010001577A1 CL 2010001577 A CL2010001577 A CL 2010001577A CL 2010001577 A CL2010001577 A CL 2010001577A CL 2010001577 A1 CL2010001577 A1 CL 2010001577A1
Authority
CL
Chile
Prior art keywords
nifurtimox
treatment
giardias
prepare
diseases caused
Prior art date
Application number
CL2010001577A
Other languages
English (en)
Inventor
Thomas Bach
Gisela Greif
Achim Harder
Gabriele Petry
Eva-Maria Kruedewaden
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CL2010001577A1 publication Critical patent/CL2010001577A1/es
Priority to CL2013000709A priority Critical patent/CL2013000709A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Catching Or Destruction (AREA)

Abstract

USO DE NIFURTIMOX PORQUE SIRVE PARA LA PREPARACIÓN DE MEDICAMENTOS PARA EL TRATAMIENTODE ENFERMEDADES CAUSADAS POR GIARDIAS.
CL2010001577A 2008-07-02 2010-12-27 Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. CL2010001577A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2013000709A CL2013000709A1 (es) 2008-07-02 2013-03-15 Composicion que contiene nifurtimox y un antihelmintico seleccionado de: pf1022, emopdepsido, tribendimidina, amidantel, bay d 9216, praziquantel o benzoato de bencilo; util en el tratamiento de enfermedades causadas por giardias (div. sol. 1577-10).

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008031284A DE102008031284A1 (de) 2008-07-02 2008-07-02 Neue Bekämpfungsmöglichkeit der Giardiose

Publications (1)

Publication Number Publication Date
CL2010001577A1 true CL2010001577A1 (es) 2011-05-06

Family

ID=41077987

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2010001577A CL2010001577A1 (es) 2008-07-02 2010-12-27 Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
CL2013000709A CL2013000709A1 (es) 2008-07-02 2013-03-15 Composicion que contiene nifurtimox y un antihelmintico seleccionado de: pf1022, emopdepsido, tribendimidina, amidantel, bay d 9216, praziquantel o benzoato de bencilo; util en el tratamiento de enfermedades causadas por giardias (div. sol. 1577-10).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2013000709A CL2013000709A1 (es) 2008-07-02 2013-03-15 Composicion que contiene nifurtimox y un antihelmintico seleccionado de: pf1022, emopdepsido, tribendimidina, amidantel, bay d 9216, praziquantel o benzoato de bencilo; util en el tratamiento de enfermedades causadas por giardias (div. sol. 1577-10).

Country Status (29)

Country Link
US (1) US8440612B2 (es)
EP (1) EP2310018B1 (es)
JP (1) JP5627579B2 (es)
KR (1) KR101720805B1 (es)
CN (1) CN102083441B (es)
AR (1) AR072425A1 (es)
AU (1) AU2009266125B2 (es)
BR (1) BRPI0913889B1 (es)
CA (1) CA2729730C (es)
CL (2) CL2010001577A1 (es)
CO (1) CO6321270A2 (es)
CR (1) CR20110022A (es)
DE (1) DE102008031284A1 (es)
DK (1) DK2310018T3 (es)
DO (1) DOP2010000405A (es)
EC (1) ECSP10010720A (es)
ES (1) ES2444581T3 (es)
IL (1) IL209698A (es)
MX (1) MX2010014446A (es)
MY (1) MY157007A (es)
NI (1) NI201100008A (es)
NZ (1) NZ590276A (es)
PE (1) PE20110283A1 (es)
PL (1) PL2310018T3 (es)
RU (1) RU2538713C9 (es)
SV (1) SV2011003785A (es)
UA (1) UA103328C2 (es)
WO (1) WO2010000399A1 (es)
ZA (1) ZA201009225B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9173898B2 (en) * 2010-10-12 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating giardiasis
WO2016187534A1 (en) 2015-05-20 2016-11-24 Merial, Inc. Anthelmintic depsipeptide compounds
SG11201805368YA (en) 2015-12-28 2018-07-30 Merial Inc Anthelmintic depsipeptide compounds
WO2018093920A1 (en) 2016-11-16 2018-05-24 Merial, Inc. Anthelmintic depsipeptide compounds
EP3750527A1 (en) * 2019-06-13 2020-12-16 Bayer AG Stable tablet formulation of nifurtimox and process for producing the same
CN114377018B (zh) * 2020-10-21 2024-02-06 中国医学科学院药物研究所 硝呋莫司在制备抗流感病毒药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1170957B (de) 1962-11-23 1964-05-27 Bayer Ag Verfahren zur Herstellung von 5-Nitro-furfuryliden-(2)-iminoderivaten
JPH081908B2 (ja) * 1987-07-22 1996-01-10 三菱電機株式会社 超格子半導体素子
NO176766C (no) * 1989-02-07 1995-05-24 Meiji Seika Kaisha Fremgangsmåte for fremstilling av en forbindelse med anthelmintaktivitet
AU669883B2 (en) 1992-03-17 1996-06-27 Astellas Pharma Inc. Depsipeptide derivative, production thereof and use thereof
DE4317458A1 (de) 1992-06-11 1993-12-16 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
CA2155871A1 (en) 1993-02-19 1994-09-01 Makoto Ohyama Derivatives of cyclodepsipeptide pf 1022
DE4317432A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
DE4317457A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
EP0718293B1 (en) 1993-09-06 2002-03-13 Fujisawa Pharmaceutical Co., Ltd. Cyclodepsipeptide compound
DE4401389A1 (de) 1994-01-19 1995-07-20 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 12 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 12 Ringatomen und Verfahren zu ihrer Herstellung
DE4406025A1 (de) 1994-02-24 1995-08-31 Bayer Ag Milchsäure-haltige cyclische Depsipeptide mit 18 Ringatomen als endoparasitizide Mittel und Verfahren zu ihrer Herstellung
DE4437198A1 (de) 1994-10-18 1996-04-25 Bayer Ag Verfahren zur Sulfonylierung, Sulfenylierung und Phosphorylierung von cyclischen Depsipeptiden
US5856436A (en) 1995-06-30 1999-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide derivative, process for production thereof, and novel intermediate therefor
BR9610527A (pt) 1995-09-22 1999-12-21 Meiji Sheika Kaisha Ltd Novos derivados de substâncias de ciclodepsipeptìdeo pf1022
DE19545639A1 (de) 1995-12-07 1997-06-12 Bayer Ag Verfahren zur Herstellung von substituierten Arylmilchsäure-haltigen Cyclodepsipeptiden mit 24 Ringatomen
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US5874630A (en) * 1998-01-06 1999-02-23 Occidental Chemical Corporation Synthesis of mercaptans from alcohols
US6133228A (en) * 1998-05-28 2000-10-17 Firmenich Sa Slow release of fragrant compounds in perfumery using 2-benzoyl benzoates, 2-alkanoyl benzoates or α-keto esters
DE19828047A1 (de) * 1998-06-24 1999-12-30 Bayer Ag Substituierte Cyclooctadepsipeptide
MX2007005570A (es) * 2004-11-12 2007-07-09 Celgene Corp Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
DE102005033496A1 (de) 2005-07-19 2007-01-25 Bayer Healthcare Ag Desinfektionsmittel

Also Published As

Publication number Publication date
NZ590276A (en) 2012-12-21
BRPI0913889A2 (pt) 2015-10-27
CN102083441A (zh) 2011-06-01
RU2011103475A (ru) 2012-08-10
CA2729730A1 (en) 2010-01-07
MX2010014446A (es) 2011-02-22
AU2009266125B2 (en) 2015-06-04
RU2538713C2 (ru) 2015-01-10
US8440612B2 (en) 2013-05-14
IL209698A0 (en) 2011-02-28
US20110105388A1 (en) 2011-05-05
JP2011526265A (ja) 2011-10-06
CA2729730C (en) 2016-03-22
CO6321270A2 (es) 2011-09-20
KR20110031357A (ko) 2011-03-25
SV2011003785A (es) 2011-05-20
ES2444581T3 (es) 2014-02-25
DK2310018T3 (da) 2014-03-24
IL209698A (en) 2016-03-31
ZA201009225B (en) 2012-03-28
HK1158113A1 (en) 2012-07-13
UA103328C2 (uk) 2013-10-10
JP5627579B2 (ja) 2014-11-19
ECSP10010720A (es) 2011-01-31
RU2538713C9 (ru) 2015-08-20
MY157007A (en) 2016-04-15
NI201100008A (es) 2011-08-10
CR20110022A (es) 2011-05-10
DE102008031284A1 (de) 2010-01-07
BRPI0913889B1 (pt) 2019-02-05
WO2010000399A1 (de) 2010-01-07
EP2310018A1 (de) 2011-04-20
EP2310018B1 (de) 2013-12-18
DOP2010000405A (es) 2011-01-15
KR101720805B1 (ko) 2017-03-28
PE20110283A1 (es) 2011-05-07
PL2310018T3 (pl) 2014-05-30
CN102083441B (zh) 2013-07-24
AU2009266125A1 (en) 2010-01-07
AR072425A1 (es) 2010-08-25
CL2013000709A1 (es) 2013-08-23

Similar Documents

Publication Publication Date Title
GT201200313A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CR20110509A (es) Composicion farmaceutica
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
SV2009003098A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CR20120419A (es) Formulación de anticuerpos y regimenes terapéuticos
CR20110407A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
MX2013011336A (es) Composiciones farmaceuticas intranasales de benzodiazepina.
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
UY31922A (es) Compuestos
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
EA201071209A1 (ru) Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови